Fibrinogen and cardiovascular disease.
作者信息
Meade T W
机构信息
MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, St Bartholomew's, London.
出版信息
J Clin Pathol. 1997 Jan;50(1):13-5. doi: 10.1136/jcp.50.1.13.
Abstract
摘要
相似文献
1
Fibrinogen and cardiovascular disease.纤维蛋白原与心血管疾病。
J Clin Pathol. 1997 Jan;50(1):13-5. doi: 10.1136/jcp.50.1.13.
2
[The occupational conditions as a risk factor in the development of cardiovascular diseases].
Vestn Ross Akad Med Nauk. 2003(12):38-41.
3
[Beta blockers, fibrinogen, and atherosclerosis].[β受体阻滞剂、纤维蛋白原与动脉粥样硬化]
Med Clin (Barc). 1994 Feb 19;102(6):231-5.
4
Fibrinogen and viscosity: risk factors for cardiovascular events.
Compr Ther. 1994;20(3):170-3.
5
Lipid management in clinical practice.临床实践中的血脂管理
Curr Opin Lipidol. 2009 Aug;20(4):350-2. doi: 10.1097/MOL.0b013e32832dd547.
6
[Outlook from the past to the future].[从过去展望未来]
Ter Arkh. 2004;76(6):8-15.
7
[Role of fibrinogen in cardiovascular diseases].
Acta Haematol Pol. 1994;25(2 Suppl 2):55-9.
8
[Fibrinogen: a "new" cardiovascular risk factor].
Wien Med Wochenschr. 1991;141(17):375-82.
9
Fibrinogen and cardiovascular risk.纤维蛋白原与心血管风险。
Vasc Med. 1997;2(2):115-25. doi: 10.1177/1358863X9700200207.
10
Reducing residual cardiovascular risk with novel therapies.
Curr Opin Lipidol. 2020 Apr;31(2):108-110. doi: 10.1097/MOL.0000000000000672.
引用本文的文献
1
Prothrombin time derived fibrinogen determination on Sysmex CA-6000.在Sysmex CA - 6000上进行凝血酶原时间衍生的纤维蛋白原测定。
J Clin Pathol. 1998 Jun;51(6):462-6. doi: 10.1136/jcp.51.6.462.
2
[Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection].[动脉粥样硬化作为慢性肺炎衣原体感染的后遗症]
Herz. 1998 May;23(3):185-92. doi: 10.1007/BF03044604.
3
Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis.肺炎衣原体引起的慢性动脉炎所致动脉粥样硬化：一个初步假说。
Infection. 1997 Sep-Oct;25(5):281-5. doi: 10.1007/BF01720397.
本文引用的文献
1
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.纤维蛋白原作为心血管危险因素：一项荟萃分析及文献综述
Ann Intern Med. 1993 Jun 15;118(12):956-63. doi: 10.7326/0003-4819-118-12-199306150-00008.
2
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).一项针对临床确诊的动脉粥样硬化性心脏病患者提高血清高密度脂蛋白胆固醇并降低甘油三酯的二级预防试验的原理与设计（苯扎贝特心肌梗死预防试验）
Am J Cardiol. 1993 Apr 15;71(11):909-15. doi: 10.1016/0002-9149(93)90905-r.
3
4
Fibrinogen after coronary angioplasty as a risk factor for restenosis.冠状动脉血管成形术后纤维蛋白原作为再狭窄的危险因素
Circulation. 1995 Jul 1;92(1):31-8. doi: 10.1161/01.cir.92.1.31.
5
Cholesterol reduction yields clinical benefit. A new look at old data.降低胆固醇可带来临床益处。对旧数据的新审视。
Circulation. 1995 Apr 15;91(8):2274-82. doi: 10.1161/01.cir.91.8.2274.
6
The influence of fibrinogen concentration on the development of vein graft stenoses.纤维蛋白原浓度对静脉移植物狭窄形成的影响。
Eur J Vasc Endovasc Surg. 1995 May;9(4):415-20. doi: 10.1016/s1078-5884(05)80009-7.
7
Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.老年人血浆纤维蛋白原和凝血因子VII活性的季节性变化：冬季感染与心血管疾病死亡
Lancet. 1994 Feb 19;343(8895):435-9. doi: 10.1016/s0140-6736(94)92689-1.
8
Fibrinogen as a risk factor for stroke and myocardial infarction.纤维蛋白原作为中风和心肌梗死的一个风险因素。
N Engl J Med. 1984 Aug 23;311(8):501-5. doi: 10.1056/NEJM198408233110804.
9
Haemostatic function and cardiovascular death: early results of a prospective study.止血功能与心血管死亡：一项前瞻性研究的早期结果
Lancet. 1980 May 17;1(8177):1050-4. doi: 10.1016/s0140-6736(80)91498-1.
10
Fibrinogen and risk of cardiovascular disease. The Framingham Study.纤维蛋白原与心血管疾病风险。弗明汉姆研究。
JAMA. 1987 Sep 4;258(9):1183-6.
Zotero 插件